Simple Summary The mainstay of treatment for locoregionally advanced head and neck
squamous cell carcinoma (HNSCC) is either surgery followed by adjuvant radiation therapy …

The most common cancer caused by human papillomavirus (HPV) infection in the United
States is oropharyngeal cancer (OPC), and its incidence has been rising since the turn of the …

Background Chemoradiotherapy is the standard of care for unresected locally advanced
squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab …

Human papillomavirus (HPV) infection drives tumorigenesis in the majority of cervical,
oropharyngeal, anal, and vulvar cancers. Genetic and epidemiologic evidence has …

Immunotherapy has changed the treatment landscape of Head and Neck cancer (HNC).
Different immune checkpoint inhibitors targeting PD-1/PD-L1 axis have been approved for …

Immune checkpoint blockade (ICB) improves outcomes for some patients with advanced or
metastatic cancers. Despite demonstrable progress, many patients do not respond to ICB …

Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. While this approach …

PURPOSE To provide evidence-based recommendations for practicing physicians and
other health care providers on immunotherapy and biomarker testing for head and neck …

Background Concurrent chemoradiotherapy has been the standard of care for locally
advanced cervical cancer for over 20 years; however, 30–40% of treated patients have …

The tumor-draining lymph nodes (TDLNs) are the primary sites of the development of anti-
tumor immunity. Primary tumor irradiation promotes 'radio-vaccination'by enhancing the …